CN105287506A - Application of sphenostylisins B to prepare medicines increasing erythrocyte - Google Patents
Application of sphenostylisins B to prepare medicines increasing erythrocyte Download PDFInfo
- Publication number
- CN105287506A CN105287506A CN201510786389.1A CN201510786389A CN105287506A CN 105287506 A CN105287506 A CN 105287506A CN 201510786389 A CN201510786389 A CN 201510786389A CN 105287506 A CN105287506 A CN 105287506A
- Authority
- CN
- China
- Prior art keywords
- erythrocyte
- sphenostylisins
- application
- prepare medicines
- sphenostylisinsb
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention relates to a new purpose of sphenostylisins B in the pharmacy field. Concretely, the invention relates to application of sphenostylisins B to prepare medicines increasing erythrocyte. The related purpose of sphenostylisins B to prepare medicines increasing erythrocyte is disclosed for the first time. Because the framework type belongs to a brand-new framework type and the inhibition activity of sphenostylisins B on erythrocyte lowness is unexpected, there is not the possibility that other compounds give any enlightenment, the technical scheme possesses prominent substantive features, and also prevention on erythrocyte lowness obviously possesses notable progress.
Description
Technical field
The present invention relates to the novelty teabag of compound S phenostylisinsB, particularly relate to the application of SphenostylisinsB in preparation rising erythrocyte medicine.
Background technology
The compound S phenostylisinsB that the present invention relates to is one and delivers (LiJ in 2012, etal., SphenostylisinsA-K:bioactivemodifiedisoflavonoidconstitu entsoftherootbarkofSphenostylismarginatassp.erecta.JOrgC hem, 2013, 78 (20): 10166-10177.) noval chemical compound, this compound has brand-new framework types, current purposes only relates to antibacterial action (LiJ, etal., SphenostylisinsA-K:bioactivemodifiedisoflavonoidconstitu entsoftherootbarkofSphenostylismarginatassp.erecta.JOrgC hem, 2013, 78 (20): 10166-10177.), brand-new structure type is belonged to for the SphenostylisinsB that the present invention relates to, in the prior art there are no the erythrocytic report of rising.
Summary of the invention
The object of the invention is to not find that it has the present situation raising erythrocytic report according in existing SphenostylisinsB research, provide the application of SphenostylisinsB in preparation rising erythrocyte medicine.
Described compound S phenostylisinsB structure is as shown in formula I:
The purposes of the SphenostylisinsB that the present invention relates in preparation treatment erythrocyte low medicine thing belongs to first public, because framework types belongs to brand-new framework types, and it is unexpectedly strong for the low inhibit activities of erythrocyte, there is not the possibility being provided any enlightenment by other compounds, possess outstanding substantive distinguishing features, for the control that erythrocyte is low, obviously there is significant progress simultaneously.
Detailed description of the invention
The preparation method of compound S phenostylisinsB involved in the present invention is see document (LiJ, etal., SphenostylisinsA-K:bioactivemodifiedisoflavonoidconstitu entsoftherootbarkofSphenostylismarginatassp.erecta.JOrgC hem, 2013,78 (20): 10166-10177.)
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not by any restriction of specific embodiment, but be limited by claim.
Embodiment 1: the preparation of compound S phenostylisinsB tablet involved in the present invention:
Get 5 g of compound SphenostylisinsB and add starch 195 grams, mixing, Conventional compression makes 1000.
Embodiment 2: the preparation of compound S phenostylisinsB capsule involved in the present invention:
Get 5 g of compound SphenostylisinsB and add 195 grams, dextrin, mixing, encapsulatedly makes 1000.
Its pharmaceutically active is further illustrated below by pharmacodynamic experiment.
One, SphenostylisinsB is to the therapeutical effect of post hemorrhagic mice
ICR mice 40 is got on the impact of post hemorrhagic mice, ♀ ♂ half and half, Nanjing Medical University's Experimental Animal Center, be divided into 4 groups (n=10).Except normal saline group, other group every mice, from orbital vein blood-letting 0.5ml, is got blood survey again and all respectively organizes index after 24h, then continuous gastric infusion 1 week, after last administration 1h, gets the full whole bliid platelet analyzer of blood F-800 survey These parameters from orbital venous plexus.
Table 1SphenostylisinsB is to because of oligocythemic therapeutical effect caused by losing blood
Compare with model group: * p<0.05**p<0.01
Result shows, blood-letting mice is after taking SphenostylisinsB and treating 7 days, and 2 administration groups compare respectively at model group, and its erythrocyte is significantly higher than model group, close to normal saline group.
Two, SphenostylisinsB causes oligocythemic therapeutical effect to cyclophosphamide
To the preventive and therapeutic effect ICR mice 40 of mouse bone marrow cells hemopoietic function damage, ♀ ♂ dual-purpose, Nanjing Medical University's Experimental Animal Center, be divided into 4 groups (n=10), i.e. normal saline group, modeling group, 1.2mg/kg group and 0.6mg/kg group, oral administration, every day 1 time.0th, except normal saline group, other respectively organized mice lumbar injection cycli phosphate amine 80mg/kg respectively, then continued administration 3 days on 5th, 10.1h after last administration, gets blood from orbital venous plexus, surveys erythrocyte, gets femur bone marrow counting number of nucleated cells.
Table 2SphenostylisinsB is on the erythrocytic impact of caused by cyclophosphamide
Compare with normal saline group: * p<0.05**p<0.01
Result shows, compares with normal saline group, and cycli phosphate amine can make mouse bone marrow cells damage, and causes peripheral blood cells to decline, and SphenostylisinsB group compares with model group, all obviously can resist the red decline of cycli phosphate amine induced mice.
Three, SphenostylisinsB is to oligocythemic therapeutical effect caused by benzene
Kunming mouse 48 is affected, ♀ ♂ dual-purpose, Nanjing Medical University's Experimental Animal Center to Induced Aplastic Anemia Mice, be divided into 4 groups (n=12), except normal saline group, other group mouse subcutaneous injection benzene 0.5ml/kg, continuous 12 days, the same day of modeling, simultaneously oral administration, every day 1 time, totally 18 days, 1h after last administration, orbital venous plexus gets blood, survey erythrocyte, get femur bone marrow counting number of nucleated cells.
Table 3SphenostylisinsB is to oligocythemic therapeutical effect caused by benzene
Compare with model group: * p<0.05**p<0.01
Result shows, 2 administration groups compare respectively at model group, all obviously can resist the erythrocytic decline of Induced Aplastic Anemia Mice caused by benzene.
Conclusion: SphenostylisinsB significantly can raise erythrocyte, can be used for preparing raising erythrocytic medicine.
Claims (1)
1.SphenostylisinsB is raising the application in erythrocyte medicine, and described compound S phenostylisinsB structure is as shown in formula I:
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510786389.1A CN105287506A (en) | 2015-11-16 | 2015-11-16 | Application of sphenostylisins B to prepare medicines increasing erythrocyte |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510786389.1A CN105287506A (en) | 2015-11-16 | 2015-11-16 | Application of sphenostylisins B to prepare medicines increasing erythrocyte |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105287506A true CN105287506A (en) | 2016-02-03 |
Family
ID=55185798
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510786389.1A Pending CN105287506A (en) | 2015-11-16 | 2015-11-16 | Application of sphenostylisins B to prepare medicines increasing erythrocyte |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105287506A (en) |
-
2015
- 2015-11-16 CN CN201510786389.1A patent/CN105287506A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105456272A (en) | Application of Biscarpamontamine A in preparing medicine for increasing red blood cells | |
| CN105287506A (en) | Application of sphenostylisins B to prepare medicines increasing erythrocyte | |
| CN103271913A (en) | Application of Myriberine A in preparing thrombocyte-increasing medicines | |
| CN103720686B (en) | Trigoxyphin K is raising the application in erythrocyte medicine | |
| CN103462956B (en) | Application of Nardoaristolones A in preparation of medicaments for increasing erythrocytes | |
| CN103417549B (en) | Application of compound Kadcoccitones A in preparation of erythrocyte increasing drugs | |
| CN103356648B (en) | Chukrasone A raises the application in erythrocytic medicine in preparation | |
| CN105343066A (en) | Application of Herqueidiketal in preparing erythrocyte increasing medicine | |
| CN105287490A (en) | Application of Hydroxyartoflavone A in preparation of medicine for increasing red blood cells | |
| CN105476987A (en) | Application of Penibruguieramine A to preparation of medicine for increasing red blood cells | |
| CN105380952A (en) | Application of Astataricusones C in preparation of drugs for raising erythrocyte level | |
| CN103356642B (en) | The application of Chukrasone A in the medicine preparing leukocyte increasing | |
| CN103372001B (en) | The application of Chukrasone B in the medicine preparing leukocyte increasing | |
| CN105250264A (en) | Application of Daphniyunnine B to preparation of medicine for increasing erythrocytes | |
| CN103751178B (en) | The application of Trigoxyphin K in increased platelets counts medicine | |
| CN103372018B (en) | The application of Chukrasone A in the medicine of preparation increased platelets counts | |
| CN102988392B (en) | Application of Houttuynoid B in preparation of medicine for rising red blood cells | |
| CN103271917A (en) | Application of Myriberine A in preparing erythrocyte-increasing medicines | |
| CN103285011A (en) | Application of Aspeverin in red blood cell increase drug preparation | |
| CN106420705A (en) | Application of Sorgomol in preparing medicine for increasing erythrocyte | |
| CN103463105A (en) | Application of Phyllanthoid A in preparing medicament for increasing erythrocytes | |
| CN105287523A (en) | Use of Alistonitrine A in preparation of drug for increasing platelet | |
| CN105456244A (en) | Application of Flabelliferin A in preparation of platelet improving drugs | |
| CN106309429A (en) | Application of Linderolide-H in preparation of medicaments for increasing erythrocytes | |
| CN102988380A (en) | Application of Houttuynoid B to preparation of medicine for rising white blood cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160203 |
|
| WD01 | Invention patent application deemed withdrawn after publication |